You are here

Journal > Immunology

Therapeutic Advances in Vaccines and Immunotherapy

Managing Editor
Philip Shaw SAGE Publications Ltd, London, UK
eISSN: 25151363 | ISSN: 25151355 | Current volume: 11 | Current issue: 1 Frequency: Yearly
Download flyer Recommend to Library

Journal Highlights

  • Launched in 2013
  • Gold open access journal – all articles are made freely available online immediately upon publication
  • Rigorous peer review
  • Listed in PubMed
  • Free to publish in for an introductory period

Therapeutic Advances in Vaccines and Immunotherapy is a peer-reviewed open access journal which focuses on all areas of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as an ever-growing repertoire of other immunotherapeutic interventions. Please see the aims and scope for further information.

Diversity, Equity and Inclusion Statement

Therapeutic Advances in Vaccines and Immunotherapy promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the research community.

Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.

We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.

We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.

Submission information

Submit your manuscript today at https://mc.manuscriptcentral.com/tav.

Please see the submission guidelines tab for more information on how to submit your article to the journal.

Open access information

There are no article processing charges (APCs) for regular articles. The APC for a Plain Language Summary is 4500 USD.

Contact

Please direct any queries to philip.shaw@sagepub.co.uk.

This journal changed its publication mode from subscription to open access in 2019.

Therapeutic Advances in Vaccines and Immunotherapy delivers the highest quality peer-reviewed open access articles, reviews, and scholarly comment relating to advances in the fields of vaccinology and immunotherapy. The journal covers all research relevant to the prospects of recovering a natural, or enhancing an induced, immune response, reporting on advances in vaccination (both prophylactic and therapeutic) as well as an ever-growing repertoire of other immunotherapeutic interventions.
Therapeutic Advances in Vaccines and Immunotherapy covers themes including but not limited to:
 
  • Immunotherapy for Cancer
  • Vaccine Development
  • Personalised Immunotherapy
  • Vaccine Adjuvants and Formulation
  • Immunotherapeutic Targets
  • Immunotherapy and Autoimmune Diseases
  • Vaccine Delivery Systems
  • Immune Response Monitoring
  • Vaccination Strategies in low-resource settings
  • Vaccine strategies in emerging Infectious Diseases
  • Ethical and Regulatory Considerations
  • Global Health policies on Access to Vaccines
  • Vaccine Hesitancy and Communication
  • Immune Memory and Long-Term Protection
  • Vaccine Safety and Adverse Events
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
 
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, post-marketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Vaccines and Immunotherapy conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
 
The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of acceptance.
 
Managing Editor
Bushra Mahdi Sage Publications Ltd, United Kingdom
Assistant Managing Editor
Ashima Sinha SAGE Publications India Pvt Ltd, New Delhi, India
Associate Editors
Christopher S. Ambrose AstraZeneca, Washington DC, USA
Said Dermime National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
E. David G. McIntosh Imperial College, London, UK
Peter L. Stern University of Manchester, Manchester, UK
Editorial Board
Mark Alderson Path, Seattle, USA
Shai Ashkenazi Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
Stan L. Block Kentucky Pediatric and Adult Research Inc., Bardstown, KY, United States
Paolo Bonanni Public Health Department, University of Florence, Florence, Italy
Robert Booy Children's Hospital Westmead, The University of Sydney, NSW, Australia
Rodrigo DeAntonio CEVAXIN, Panama City, Panama
Susanna Esposito Università degli Studi di Perugia, Perugia, Italy
Alison N. Fiander School of Medicine, Cardiff University, Cardiff, UK
Suzanne M. Garland The Royal Women’s Hospital, Parkville, Australia
Jamie Honeychurch The University of Manchester, UK
Samir Khleif Augusta University, USA
Matti Lehtinen University of Tampere, School of Public Health, Tampere, Finland
Helen S. Marshall Women’s and Children’s Hospital, University of Adelaide, SA, Australia
Cornelis Melief Leiden University Medical Center, The Netherlands
Magdalini Moutaftsi European & Developing Countries Clinical Trials Partnership (EDCTP), The Hague Area, The Netherlands
Adrian Onu Cantacuzino National Medico-Military Research and Development Institute, Bucharest, Romania
Sanjay Phogat Sanofi Pasteur, Swiftwater, PA, USA
Heinz-Josef Schmitt Pfizer, Paris, France
Bart Tarbet Utah State University, USA
Miriam Tendler Institute Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brasil, Brazil
Usa Thisyakorn Faculty of Engineering, Mahidol University, Thailand
Wiebren Tjalma Antwerp University Hospital, Edegem, Belgium
Sudhandshu Vrati Regional Centre for Biotechnology, Faridabad, India
  • Directory of Open Access Journals (DOAJ)
  • ProQuest
  • PubMed Central (PMC)
  • Scopus

Manuscript submission guidelines can be accessed on Sage Journals.